A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
מצבים רפואיים
Non-muscle-invasive Bladder Cancer · NMIBC · Non-Muscle Invasive Bladder Carcinoma · Non-Muscle Invasive Bladder Neoplasms · Non-Muscle Invasive Bladder Urothelial Carcinoma · Urothelial Carcinoma Bladder
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Arkansas Urology, Little Rock, Arkansas, United States
Tower Urology, Los Angeles, California, United States
Contact: Principal Investigator (David Josephson)Saint John's Cancer Institute, Santa Monica, California, United States
Montefiore Medical Center, The Bronx, New York, United States
Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Urology Associates, P.C., Nashville, Tennessee, United States
Urology Clinics of North Texas, Dallas, Texas, United States
Baylor College of Medicine, Houston, Texas, United States
The University of Texas San Antonio, San Antonio, Texas, United States
Urology San Antonio/USA Clinical Trials, San Antonio, Texas, United States
The Urology Place, San Antonio, Texas, United States
Westmead Private Hospital, Westmead, New South Wales, Australia
Contact: Principal Investigator (Manish Patel)Austin Health, Heidelberg, Victoria, Australia
Contact: Principal Investigator (Joseph Ischia)Warringal Private Hospital, Heidelberg, Victoria, Australia
Contact: Principal Investigator (Damien Bolton)Penninsula Private Hospital, Langwarrin, Victoria, Australia
Contact: Principal Investigator (George Koufogiannis)The Royal Melbourne Hospital, Parkville, Victoria, Australia
Contact: Study coordinator (Avanthika Lakshmanan) · Avanthika.Lakshmanan@mh.org.au · +61 3 9342 7294Contact: Principal Investigator (Paul Anderson)Hollywood Private Hospital, Nedlands, Western Australia, Australia
Contact: Principal Investigator (Tom Shannon)
מובילי המחקר
Medical Monitor
Study Director
Aura Biosciences